Jansen to Lead Product Expansion Focused on Essential Medicines Facing Access Challenges SAN FRANCISCO – July 17, 2020 – Medicines360, a global nonprofit women’s health pharmaceutical organization, has appointed Rolf Jansen as the Vice President of Drug Development and Manufacturing. Mr. Jansen is a chemical engineer with more than thirty years of pharmaceutical experience developing […]
Newly Published Data from Phase 3 Clinical Trial of LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg Reinforces Efficacy for Longest-Approved Duration of Use for a Hormonal IUS
SAN FRANCISCO – December 17, 2019 – Medicines360, a global nonprofit women’s health pharmaceutical company, announced newly published data finding that LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg is highly efficacious in preventing pregnancy for up to six years of use. The publication also reports data related to the bleeding profile over the same period of […]
FDA Approves Medicines360’s LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Six Years, the Longest Approved Duration of Use of Any Hormonal IUDs
SAN FRANCISCO and DUBLIN – Medicines360, a global nonprofit organization with a mission to expand women’s access to quality medicines, and Allergan plc (NYSE: AGN), a leading global pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved Medicines360’s Supplemental New Drug Application (sNDA) to extend the duration of use of LILETTA® (levonorgestrel-releasing […]
Medicines360 Launches #NotAwkward Campaign to Encourage Positive Conversations about Birth Control and Reproductive Health
New survey finds the top access challenge cited by women is feeling uncomfortable discussing sex or birth control SAN FRANCISCO (September 16, 2019) – Medicines360, a nonprofit women’s health organization tackling the most pressing needs in women’s health, today announced the launch of #NotAwkward, a campaign to encourage positive conversations about birth control and reproductive […]
SAN FRANCISCO – Medicines360, a nonprofit, global women’s health pharmaceutical company with a mission of expanding access to quality medicines, was awarded the Clinical Trial Result of the Year at the 2019 Clinical and Research Excellence (CARE) Awards. The CARE Awards celebrate the achievements of those working to advance the quality of healthcare worldwide by bringing […]
Medicines360 and Allergan Present Six-Year Clinical Data from Largest Ongoing Phase 3 Study of an Intrauterine System in the U.S.
Six-Year, Multi-Center, Pivotal Clinical Trial Data of LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg Presented at 2019 ACOG Meeting SAN FRANCISCO and DUBLIN – Medicines360, a nonprofit women’s health pharmaceutical company with a mission of expanding access to quality medicines, and Allergan plc (NYSE: AGN), a leading global pharmaceutical company, presented new six-year data from Medicines360’s ongoing […]
SANTA BARBARA INDEPENDENT – Direct Relief’s Kirchmaier Volunteer Center was standing room only Friday morning, March 8, as more than 150 people gathered in honor of International Women’s Day to celebrate achievements and acknowledge remaining hurdles, including the lack of global access to affordable maternal health care. This year’s theme was “balance for better — […]
Medicines360, Afaxys Partner to Expand Public Health Access to LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg
Strategic alliance will increase engagement with U.S. public health clinics and their patients about hormonal IUDs (long-acting reversible contraceptives, or LARCs) SAN FRANCISCO and CHARLESTON, S.C. – Medicines360 and Afaxys Pharma, LLC, two mission-driven, socially conscious women’s health pharmaceutical companies, today announced their collaboration to promote Medicines360’s intrauterine system (IUS), LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg, which is […]
FORBES – Medicines360, the non-profit pharmaceutical company behind the hormonal IUD Liletta, is on a mission to increase women’s access to reproductive care around the world. This month, the female-led company announced the launch of Avibela, a hormonal IUD, in Madagascar.